* If you want to update the article please login/register
The use of point-of-care global coagulation tests such as ROTEM and Sonoclot helps us determine the true prothrombotic and hypocoagulable states that can be used to determine increased clot strength, clot formation time, and hyperfibrinolysis. Patients with therapeutic anticoagulation for HVOTO/PVT may also be able to identify the role of global coagulation tests rather than PT/INR /aPTT in tracking the dose and response of anticoagulants like vitamin K antagonists and novel oral anticoagulants in patients with chronic anticoagulation therapy for HVOTO/PVT. In patients with PVT and HVOTO in our population, this report will also help to determine the presence and role of CALR, JAK2V617F, factor V Leiden mutations. In the post-COPVID-19 period, we'll also be prospectively examining the risk of thrombophilia issues, and the report will provide insight into the current incidence of PVT/HVOTO in those exposed to COVID-19.
Source link: https://clinicaltrials.gov/ct2/show/NCT05123326
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions